RT info:eu-repo/semantics/article
T1 Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies
A1 Olivares Hernández, Alejandro
A1 Figuero Pérez, Luis
A1 Terán Brage, Eduardo
A1 López Gutiérrez, Álvaro
A1 Tamayo Velasco, Álvaro
A1 González Sarmiento, Rogelio
A1 Cruz Hernández, Juan Jesús
A1 Miramontes González, José Pablo
K1 Hematology
K1 Oncology
K1 Blood - Diseases
K1 Sangre - Enfermedades
K1 Immunology
K1 Médula ósea - Tumores
K1 Cancer research
K1 Myeloid-derived suppressor cells (MDSCs)
K1 Células mieloides supresoras (MDSCs)
K1 Immune checkpoint inhibitors (ICIs)
K1 Inhibidores del punto de control inmunitario (ICI)
K1 Immune resistance
K1 Resistencia inmune
K1 3207.08 Hematología
K1 3207.13 Oncología
AB Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.
PB MDPI
SN 2077-0383
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/59700
UL https://uvadoc.uva.es/handle/10324/59700
LA eng
NO Journal of Clinical Medicine, 2021, Vol. 10, Nº. 9, 1919
NO Producción Científica
DS UVaDOC
RD 12-ene-2025